Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Protagonist Therapeutics, Inc (PTGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.11 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-25
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-06-30 was 64.00K shares, a 80.16% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-03-31 was 2.20M shares, a 95.95% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-12-31 was 166.70K shares, a 467.01% increase year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2022-09-30 was 152.00K shares, a 53.01% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.11M shares, a 46.18% decline from fiscal 2024.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.07M shares, a 17.91% decline from fiscal 2023.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.52M shares, a 42.90% increase from fiscal 2022.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.76M shares, a 9.57% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 1.11M shares 10-K · filed 2026-02-25 | |||
| 2024-12-31 | 2.07M shares 10-K · filed 2025-02-21 | |||
| 2023-12-31 | 2.52M shares 10-K · filed 2024-02-27 | |||
| 2023-06-30 | 64.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.26M shares 10-Q · filed 2023-08-03 | 2.43M shares derived: sum of 3 quarters · filed 2023-08-03 | 2.58M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 2.20M shares 10-Q · filed 2023-05-04 | 2.37M shares derived: sum of 2 quarters · filed 2023-05-04 | 2.52M shares derived: sum of 3 quarters · filed 2023-05-04 | 2.84M shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 166.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 318.70K shares derived: sum of 2 quarters · filed 2023-03-15 | 641.20K shares derived: sum of 3 quarters · filed 2023-03-15 | 1.76M shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 152.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 474.50K shares derived: sum of 2 quarters · filed 2022-11-08 | 1.60M shares 10-Q · filed 2022-11-08 | 1.63M shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 322.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 1.44M shares 10-Q · filed 2022-08-04 | 1.47M shares derived: sum of 3 quarters · filed 2022-08-04 | 1.80M shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 1.12M shares 10-Q · filed 2022-05-05 | 1.15M shares derived: sum of 2 quarters · filed 2022-05-05 | 1.48M shares derived: sum of 3 quarters · filed 2022-05-05 | 1.91M shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 29.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 352.90K shares derived: sum of 2 quarters · filed 2022-02-28 | 791.10K shares derived: sum of 3 quarters · filed 2022-02-28 | 1.95M shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 323.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 761.70K shares derived: sum of 2 quarters · filed 2021-11-03 | 1.92M shares 10-Q · filed 2021-11-03 | 2.09M shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 438.20K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 1.60M shares 10-Q · filed 2021-08-04 | 1.76M shares derived: sum of 3 quarters · filed 2021-08-04 | 1.99M shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 1.16M shares 10-Q · filed 2021-05-04 | 1.32M shares derived: sum of 2 quarters · filed 2021-05-04 | 1.55M shares derived: sum of 3 quarters · filed 2021-05-04 | 1.72M shares derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | 165.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | 394.80K shares derived: sum of 2 quarters · filed 2021-03-10 | 558.80K shares derived: sum of 3 quarters · filed 2021-03-10 | 1.54M shares 10-K · filed 2021-03-10 |
| 2020-09-30 | 229.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 393.00K shares derived: sum of 2 quarters · filed 2020-11-04 | 1.37M shares 10-Q · filed 2020-11-04 | 1.43M shares derived: sum of 4 quarters · filed 2020-11-04 |
| 2020-06-30 | 164.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 1.14M shares 10-Q · filed 2020-08-06 | 1.20M shares derived: sum of 3 quarters · filed 2020-08-06 | 1.40M shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 977.60K shares 10-Q · filed 2020-05-07 | 1.04M shares derived: sum of 2 quarters · filed 2020-05-07 | 1.24M shares derived: sum of 3 quarters · filed 2020-05-07 | 1.52M shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 63.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | 261.50K shares derived: sum of 2 quarters · filed 2020-03-10 | 540.50K shares derived: sum of 3 quarters · filed 2020-03-10 | 1.33M shares 10-K · filed 2020-03-10 |
| 2019-09-30 | 198.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 477.50K shares derived: sum of 2 quarters · filed 2019-11-06 | 1.27M shares 10-Q · filed 2019-11-06 | 303.35K shares derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | 279.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | 1.07M shares 10-Q · filed 2019-08-07 | 104.85K shares derived: sum of 3 quarters · filed 2019-08-07 | 299.30K shares derived: sum of 4 quarters · filed 2019-08-07 |
| 2019-03-31 | 788.30K shares 10-Q · filed 2019-05-08 | -174.15K shares derived: sum of 2 quarters · filed 2019-05-08 | 20.30K shares derived: sum of 3 quarters · filed 2019-05-08 | 201.30K shares derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | -962.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -768.00K shares derived: sum of 2 quarters · filed 2019-03-12 | -587.00K shares derived: sum of 3 quarters · filed 2019-03-12 | 42.95K shares 10-K · filed 2019-03-12 |
| 2018-09-30 | 194.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | 375.45K shares derived: sum of 2 quarters · filed 2018-11-06 | 1.01M shares 10-Q · filed 2018-11-06 | |
| 2018-06-30 | 181.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 810.95K shares 10-Q · filed 2018-08-07 | ||
| 2018-03-31 | 629.95K shares 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |